Cronos Group/$CRON
1D1W1MYTD1Y5YMAX
Capital at risk
About Cronos Group
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
- Ticker
- $CRON
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 610
- Headquarters
- Stayner, Canada
- Website
- thecronosgroup.com
Cronos Group Metrics
BasicAdvanced
$1.2B
17.28
$0.18
1.24
-
Price and volume
Market cap
$1.2B
Beta
1.24
52-week high
$3.61
52-week low
$2.28
Average daily volume
1.5M
Financial strength
Current ratio
16.181
Quick ratio
15.153
Long term debt to equity
0.101
Total debt to equity
0.116
Profitability
EBITDA (TTM)
11.879
Gross margin (TTM)
43.02%
Net profit margin (TTM)
39.08%
Operating margin (TTM)
-1.03%
Effective tax rate (TTM)
-15.67%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-0.10%
Return on equity (TTM)
7.05%
Valuation
Price to earnings (TTM)
17.279
Price to revenue (TTM)
6.752
Price to book
1.52
Price to tangible book (TTM)
1.63
Price to free cash flow (TTM)
24.458
Free cash flow yield (TTM)
4.09%
Free cash flow per share (TTM)
0.13
Growth
Revenue change (TTM)
37.46%
Earnings per share change (TTM)
282.07%
3-year revenue growth (CAGR)
30.30%
10-year revenue growth (CAGR)
59.89%
3-year earnings per share growth (CAGR)
-21.27%
10-year earnings per share growth (CAGR)
32.60%
What the Analysts think about Cronos Group
Analyst ratings (Buy, Hold, Sell) for Cronos Group stock.
Analyst projections of the future price of Cronos Group stock.
Bulls say / Bears say
Cronos’ Q2 2026 results delivered net revenue of $53 million, a 58% YoY increase, and adjusted EPS of $0.09 versus $0.01 estimate, boosting shares 13.24% in premarket trading (Reuters).
Gross profit nearly doubled year-over-year to $28.5 million, and record adjusted EBITDA reached $13.1 million in Q2 2026, driven by higher selling prices, favorable product mix and operational efficiencies (Reuters).
Cronos ended Q2 2026 with $827 million in cash, equivalents and short-term investments, and returned $60 million to shareholders via buybacks, underscoring robust liquidity and disciplined capital allocation (Reuters).
Two customers accounted for 44% of Cronos’ Q2 2026 net revenue before excise taxes, indicating significant customer concentration risk (SEC Form 10-Q).
Cronos Israel faces heightened regulatory risk after Israel’s Trade Levies Commissioner opened an anti-dumping investigation into Canadian medical cannabis imports on June 29, 2026, which could restrict production, import, or sales in a key market (SEC Form 10-Q).
Cronos remains vulnerable to negative market sentiment, as Bloomberg reported former short-seller Andrew Left’s 2018 short report on Cronos was cited in a May 2026 federal trial, underscoring susceptibility to adverse short-seller campaigns (Bloomberg).
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Cronos Group Financial Performance
Revenues and expenses
Cronos Group Earnings Performance
Company profitability
Upcoming events
No upcoming events
Cronos Group News
AllArticlesVideos
Funds containing Cronos Group
AllEURUSDGBP
Fund name | Fund size | $CRON weighting |
|---|---|---|
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
iShares MSCI World Small Cap$WSML | $9B | 0.00% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.00% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.